What information does the manufacturer of Seleniso include?

Selinexor is the first XPO1 nuclear export inhibitor developed and produced by Karyopharm Therapeutics Inc., an American pharmaceutical company, with the trade name Xpovio. As an oral anti-cancer drug with an innovative mechanism, the drug is mainly used to treat multiple myeloma and relapsed and refractory diffuse large B-cell lymphoma. It has been approved for marketing by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) of the European Union. Karyopharm is currently the only core manufacturer in the world that owns the patent, R&D and commercial rights of this drug.

Karyopharm Therapeutics is a biopharmaceutical company focusing on the research and development of nuclear transport protein target drugs. The company's R&D pipeline mainly revolves around SINE compounds. Selinisol is its first representative product successfully commercialized and the world's first XPO1 inhibitor to enter clinical use. In terms of production, Karyopharm uses international standard GMP certified processes to manufacture selinesol raw materials and finished products. The finished products are usually in the form of tablets, and different specifications are used for different dosage adjustment needs, ensuring drug quality and clinical safety.

Patients can check the registration information, production batch number, expiration date, drug specifications and manufacturing process of Seleniso on the official website of Karyopharm, the FDA drug database (Drugs@FDA) and the official website of the European Union EMA. Pharmaceutical packaging labels generally indicate key contents such as production batch number, expiration date, storage conditions (usually placed in a dark and dry place below 25°C).

It should be noted that selinesol is a prescription anti-tumor drug. Its purchase and use must be strictly under the guidance of a doctor and issued in a medical institution. Individuals are prohibited from purchasing products privately through overseas channels to avoid quality and efficacy risks.

Reference materials:https://www.selincro.com/